CCT007093: Targeted PPM1D Inhibition and P38 MAPK Activation

Executive Summary: CCT007093 is a small-molecule PPM1D (WIP1) inhibitor with an IC₅₀ of 8.4 μM, enabling precise dissection of PPM1D-regulated signaling pathways in vitro and in vivo (product information). This compound selectively induces cytotoxicity in MCF-7 breast cancer cells and activates the P38 MAPK pathway, with effects reversible by the P38 inhibitor SB203580. Recent studies confirm that CCT007093 amplifies pyroptosis in acute kidney injury models via P38 activation (Wang et al., 2024). CCT007093 is insoluble in water and ethanol but is highly soluble in DMSO at ≥3.4 mg/mL, with optimal storage at −20°C. As a research tool, it is valuable for mechanistic studies in oncology and inflammatory kidney disease (internal article).

Biological Rationale

PPM1D (protein phosphatase, Mg2+/Mn2+ dependent 1D; also called WIP1) is a serine/threonine phosphatase that regulates stress and DNA damage responses, cell cycle progression, and inflammation. Dysregulation of PPM1D contributes to tumorigenesis and maladaptive inflammatory responses (Wang et al., 2024). In the kidney, increased PPM1D expression is observed in tubular injury and acute kidney injury (AKI) models. In cancer, PPM1D overexpression promotes proliferation and chemoresistance, making it a therapeutic target in oncology and inflammatory diseases. P38 MAPK is a key downstream effector of PPM1D, modulating cellular stress and pyroptosis signaling (related article).

Mechanism of Action of CCT007093

CCT007093 is structurally defined as (2Z,5E)-2,5-bis(thiophen-2-ylmethylidene)cyclopentan-1-one. It acts as a highly selective PPM1D inhibitor, blocking the dephosphorylation of P38 MAPK substrates in vitro. Upon PPM1D inhibition, CCT007093 increases phosphorylation of P38 MAPK within 4 hours in cellular models. This upregulation leads to enhanced downstream signaling, including activation of NLRP3 inflammasome components and increased pyroptosis in kidney epithelial cells exposed to inflammatory stimuli (Wang et al., 2024). In breast cancer cell lines, CCT007093 selectively reduces MCF-7 viability by about 40% over 48 hours, a phenotype mimicked by PPM1D siRNA knockdown and reversed by P38 blockade (APExBIO).

Evidence & Benchmarks

• CCT007093 inhibits recombinant PPM1D activity with an IC₅₀ of 8.4 μM under in vitro assay conditions (50 mM Tris-HCl, pH 7.5, at 30°C; product information).
• In MCF-7 breast cancer cells, 40% reduction in viability is observed after 48 hours at cytotoxic concentrations, with minimal effect on HeLa cells (APExBIO, product info).
• CCT007093 increases p38 MAPK phosphorylation in human kidney epithelial (HK2) cells exposed to LPS, with peak activation at 4 hours post-treatment (Wang et al., 2024).
• In LPS-induced AKI mouse models, CCT007093 administration raises cleaved-Caspase1 and GSDMD-N protein levels, intensifying pyroptosis (Wang et al., 2024).
• Selectivity and reversibility established: P38 pathway activation and cytotoxicity are reversed by SB203580 co-treatment (APExBIO, product info).
• DMSO is the only recommended solvent for preparing ≥3.4 mg/mL working stocks; compound is insoluble in water and ethanol (product info).

This article extends previous discussions—such as "Enhancing Assay Precision with CCT007093"—by systematically benchmarking in vivo inflammation outcomes and integrating oncology and nephrology use cases.

Applications, Limits & Misconceptions

CCT007093 is widely used in research models of cancer biology and acute kidney injury to interrogate the PPM1D signaling pathway and P38 MAPK activation. Its DMSO solubility (≥3.4 mg/mL) enables reliable dosing in cell culture and in vivo studies. The compound is not suitable for clinical use and is not recommended for long-term solution storage due to stability concerns. Selective cytotoxicity is cell type dependent. Mechanistic readouts (e.g., pyroptosis, P38 phosphorylation) require context-specific controls such as PPM1D RNAi or P38 inhibitors to confirm specificity.

Common Pitfalls or Misconceptions

• CCT007093 is not a pan-phosphatase inhibitor: It is highly selective for PPM1D and does not broadly inhibit other phosphatases (product info).
• Insoluble in water/ethanol: Attempts to prepare aqueous or ethanol solutions result in precipitation and loss of activity; DMSO is required.
• Not validated for clinical or diagnostic use: CCT007093 is for research applications only, with no evidence supporting therapeutic application.
• Requires P38 inhibitor controls: Attribution of biological effects to PPM1D inhibition should be confirmed by reversal with SB203580 or similar P38 pathway tools.
• Storage limitations: Working solutions are unstable over prolonged periods; fresh preparation is recommended (product info).

Workflow Integration & Parameters

• Preparation: Dissolve CCT007093 in DMSO at concentrations ≥3.4 mg/mL; do not use water or ethanol as solvents.
• Storage: Store the solid compound at −20°C; avoid repeated freeze-thaw cycles. Prepare fresh working solutions as needed.
• Cellular Assays: For MCF-7 cytotoxicity, treat cells at indicated concentrations for 48 hours; include SB203580 as a reversal control.
• AKI Models: Administer CCT007093 (dose per protocol) to LPS-challenged or ischemia-reperfusion injury mice; assay for p38 MAPK phosphorylation and pyroptosis markers at 4–24 hours post-treatment (Wang et al., 2024).
• Controls: Always compare to vehicle (DMSO) and, where possible, to PPM1D RNAi or P38 inhibitor-treated samples to confirm specificity.

Conclusion & Outlook

CCT007093, as supplied by APExBIO (B3274), provides a robust and selective tool for interrogating the PPM1D signaling pathway and P38 MAPK-mediated cellular outcomes. Its utility is demonstrated in both cancer cell cytotoxicity and kidney inflammation models, with mechanistic effects that are benchmarked and reversible. These features make CCT007093 a preferred research reagent for dissecting PPM1D function and clarifying the regulatory circuits underlying stress, repair, and inflammation. Future research will refine its application in complex disease models, focusing on pathway specificity and integrating multi-omics data, as outlined in recent peer-reviewed findings (Wang et al., 2024).